Featured Publications
Dysregulation of the endogenous cannabinoid system following opioid exposure
Mohammad Aghaei A, Saali A, Canas M, Weleff J, D'Souza D, Angarita G, Bassir Nia A. Dysregulation of the endogenous cannabinoid system following opioid exposure. Psychiatry Research 2023, 330: 115586. PMID: 37931479, PMCID: PMC10842415, DOI: 10.1016/j.psychres.2023.115586.Peer-Reviewed Original ResearchConceptsEndocannabinoid systemECS componentsBrain regionsNovel neurobiological targetsTreatment of OUDEndogenous opioid systemOpioid-related deathsEndogenous cannabinoid systemSpecific brain regionsECS dysregulationOpioid exposureOUD treatmentOpioid systemCannabinoid systemNeurobiological targetsNew medicationsPreclinical literatureCannabinoid receptorsEndogenous ligandTherapeutic potentialStudy typePresent potential targetsExposure protocolOpioidsPreclinical research
2024
American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey
Barnett B, Arakelian M, Beebe D, Ontko J, Riegal C, Siu W, Weleff J, Pope H. American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey. Psychedelic Medicine 2024, 2: 1-9. DOI: 10.1089/psymed.2023.0036.Peer-Reviewed Original ResearchSubstance use disordersAmerican psychiatristsClassic hallucinogensPsychiatric conditionsTreatment-resistant depressionTreat psychiatric conditionsMultivariate logistic regression modelFollow-up surveyResponding psychiatristsPsychiatrists' opinionsTherapeutic potentialLogistic regression modelsUnited States Food and Drug AdministrationStates Food and Drug AdministrationHallucinogensPsychiatristsFood and Drug AdministrationPublished national surveysIncreased optimismDecreased concernAssessment attributesSurvey responsesNon-parametric trend testSurvey instrumentRegression models
2023
Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges
Barnett B, Nia A, Sackett N, Weleff J. Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges. Frontiers In Psychiatry 2023, 14: 1305478. PMID: 37928914, PMCID: PMC10622752, DOI: 10.3389/fpsyt.2023.1305478.Peer-Reviewed Original Research
2022
Psychedelics in the Treatment of Substance Use Disorders
Barnett B, Weleff J. Psychedelics in the Treatment of Substance Use Disorders. Psychiatric Annals 2022, 52: 365-370. DOI: 10.3928/00485713-20220804-01.Peer-Reviewed Original ResearchSubstance use disordersPsychedelic experienceTreatment of substance use disordersLysergic acid diethylamideSubjective effectsUse disorderAcid diethylamidePlacebo-controlled trialPsychedelicsBehavioral changesTherapeutic potentialClinician concernsLife narrativesDisordersFacilitation programTreatment paradigmTherapeutic efficacyClinical trialsTreatment potentialObservational studyPsilocybinDiethylamideTrialsSubstancesOpioid